-
Mashup Score: 0
TheAZD3759 AZD3759 elicited clinical responses and had an acceptable toxicity profile when administered at a dose of 200 mg twice daily in patients with untreated EGFR-mutant non–small cell lung cancer and central nervous system metastases, according to data from the phase 2 TRUMP trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Single-agent liposomal irinotecan resulted in a similar median overall survival and progression-free survival to that achieved with topotecan in patients with small cell lung cancer that had progressed on or following frontline platinum-based chemotherapy.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Single-agent liposomal irinotecan resulted in a similar median OS and PFS to that achieved with topotecan in patients with SCLC that had progressed on or following frontline platinum-based chemotherapy. @MSKCancerCenter @myESMO @IASLC #lcsm #ELCC https://t.co/samtuCHrqG
-
-
Mashup Score: 0
Excess risk seems to reach a plateau after 30 years of smoking 2 packs a day.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#LongTerm heavy smoking quadruples likelihood of #LungCancer vs. not #Smoking 👉https://t.co/XCgWHQTVIc @MDedgeHemOnc #ELCC #Oncology https://t.co/7uz4Gftk0s
-
-
Mashup Score: 0Cemiplimab Shows Clinical Benefit for Patients With PD-L1+ NSCLC and Brain Metastases - 1 year(s) ago
At a median follow-up of 33.3 months, the median overall survival was not evaluable with cemiplimab, vs 20.7 months with chemotherapy alone, in this patient subset.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At a median follow-up of 33.3 months, the median overall survival was not evaluable with cemiplimab, vs 20.7 months with chemotherapy alone, in this patient subset. #NSCLC #lungcancer #ELCC #oncology #nursing https://t.co/OUEqCeH1J2
-
-
Mashup Score: 0Cemiplimab Shows Clinical Benefit for Patients With PD-L1+ NSCLC and Brain Metastases - 1 year(s) ago
At a median follow-up of 33.3 months, the median overall survival was not evaluable with cemiplimab, vs 20.7 months with chemotherapy alone, in this patient subset.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Cemiplimab Shows Clinical Benefit for Patients With PD-L1+ NSCLC and Brain Metastases #NSCLC #lungcancer #ELCC #oncology #nursing https://t.co/GUQjDnZM2w
-
-
Mashup Score: 3Durable efficacy of amivantamab in mutated NSCLC - 1 year(s) ago
Updated results from the CHRYSALIS trial in pretreated NSCLC with EGFR Exon 20 insertion mutations
Source: Daily ReporterCategories: Hem/Oncs, Latest HeadlinesTweet-
#ELCC Day 1 Highlight: Amivantamab long-term outcomes + biology in EGFR exon20ins+ NSCLC: - 48% pts have clinical benefit at 1yr - 47.2% pts alive at 2yrs - Baseline ctDNA alteratns in RAS/RAF/MEK assoc with less time on tx @myESMO @Piuchagarrido #LCSM https://t.co/8bsGk75lvp https://t.co/xztiQ3V6FB
-
-
Mashup Score: 0Meetings & Webinars | IASLC - 2 year(s) ago
Whether virtual or on location, thoracic oncology specialists attend IASLC meetings and webinars to discover, collaborate, and inform.
Source: IASLCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @IASLC has many exciting upcoming meetings in 2022. We hope you can join us for #ELCC, #WCLC22, #NACLC22, #ACLC22, AND #LALCA22. Each meeting promises the most novel multidisciplinary research in thoracic oncology. Save the date and learn more at https://t.co/AX3lpJp8sX #LCSM https://t.co/hR7uRO5hLf
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 3 year(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ELCC brings together European experts to present advances in #LungCancer research 👨⚕👩⚕ Join us at 👉https://t.co/VKtzxYy0YE👈 for updates at you fingertips from 25-27 March 💻 @VJOncology @myESMO @IASLC @OncoAlert #LCsm #NSCLC #SCLC #Mesothelioma #Oncology #OncoAlert https://t.co/SPUpCjUJUI
-
-
Mashup Score: 4Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 - 3 year(s) ago
PURPOSE In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab monotherapy as maintenance therapy following first-line chemotherapy for ED-SCLC. METHODS Patients with ED-SCLC, Eastern Cooperative…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#OncoAlert Report from CheckMate 451 in #JCO @ASCO_pubs. This phase III trial explored maintenance nivolumab/ipilimumab in #SCLC and did not show an OS benefit over placebo. Initially presented at #ELCC 2019 by @teekayowo #LCSM https://t.co/mm0lnhtdb7
-
-
Mashup Score: 0European Lung Cancer Virtual Congress 2021 - 3 year(s) ago
ELCC 2021 Virtual will take place online on 25-27 March 2021
Source: www.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Submit your abstract for the European Lung Cancer Congress by January 12, 2021! This @IASLC Endorsed Meeting is going virtual March 25-27, 2021. Update your knowledge in prevention, screening & early detection of lung cancer. #LCSM #ELCC https://t.co/IdIKO132eA
-
AZD3759 Elicits Responses in Untreated EGFR-Mutant NSCLC With CNS Metastases @myESMO @IASLC #lcsm #ELCC https://t.co/MyYiQBK3n9